$54.2 Million is the total value of KPCB XV Associates, LLC's 4 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2022 |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-07-21
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Twilio Inc. | 8 | Q3 2022 | 54.3% |
Rapt Therapeutics, Inc. | 8 | Q3 2022 | 43.7% |
Atara Biotherapeutics, Inc. | 8 | Q3 2022 | 27.0% |
Upstart Holdings, Inc. | 3 | Q2 2021 | 42.4% |
Augmedix, Inc. | 2 | Q2 2022 | 0.0% |
View KPCB XV Associates, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2022-10-26 |
13F-HR | 2022-07-21 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-14 |
13F-HR | 2021-10-25 |
13F-HR | 2021-07-28 |
13F-HR | 2021-05-13 |
13F-HR | 2021-02-16 |
4 | 2020-10-20 |
4 | 2020-09-11 |
View KPCB XV Associates, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.